Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
Built from Astrazeneca plc’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$184.49+0.1%Nov 13 close
Figures through September 30, 2026, from the 6-K filed October 30, 2026
AstraZeneca sells prescription medicines for cancer, heart and kidney disease, lung conditions and rare disorders to patients through healthcare systems worldwide.
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1.36TA+
JNJJohnson & Johnson$688.6BA+
MRKMerck & Co., Inc.$364.3BA
NVSNovartis AG$306.3BA
AMGNAmgen Inc.$251.9BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now AGrade B+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 26 quarters of Astrazeneca plc’s grade history. The other 24 go back to March 2018.
